AMANDA MORIARTY: Open Payments
NPI 1306596572 · SANTA BARBARA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$700 in 30 payments from 12 companies in 2025. Trend: 2023 $1,112 · 2024 $904 · 2025 $700
Food & beverage: $700
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 6 | $192 |
| ABBVIE INC. | 10 | $163 |
| Vanda Pharmaceuticals Inc. | 2 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $44 |
| Neurelis, Inc. | 2 | $44 |
| GlaxoSmithKline, LLC. | 1 | $35 |
| TOLMAR, INC. | 1 | $24 |
| Gilead Sciences, Inc. | 1 | $24 |
| Cipher Pharmaceuticals US LLC | 1 | $17 |
Products named: Fintepla, VRAYLAR, FANAPT, CAPLYTA, XIFAXAN, VALTOCO, SHINGRIX, JATENZO.
Industry payments across CA — which companies pay providers there.
